Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance of efficacy of agomelatine to prevent relapse in out-patients with major depressive disorder
2004-003981-13Phase 3Completed
- Sponsor
- Servier
- Start
- Nov 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of agomelatine in major depressive disorder (MDD), sponsored by Servier. Primary endpoints: Relapse of major depressive disorder and Long-term safety of agomelatine. Started Nov 2004; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2004-003981-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003981-13.